keyword
MENU ▼
Read by QxMD icon Read
search

Vortioxetine

keyword
https://www.readbyqxmd.com/read/28213121/determination-of-a-clinically-important-difference-and-definition-of-a-responder-threshold-for-the-ucsd-performance-based-skills-assessment-upsa-in-patients-with-major-depressive-disorder
#1
Philip D Harvey, William Jacobson, Wei Zhong, George G Nomikos, Christina Kurre Olsen, Elizabeth Merikle, Michael Cronquist Christensen
BACKGROUND: This article reports an evaluation of the psychometric properties and clinically important difference (CID) threshold of the UCSD Performance-Based Skills Assessment (UPSA) in major depressive disorder (MDD), using data from a large-scale study of the effects of vortioxetine on cognitive functioning and functional capacity in MDD patients. METHODS: Adults with moderate-to-severe recurrent MDD and self-reported cognitive dysfunction were randomized to 8 weeks of double-blind treatment with vortioxetine 10/20mg QD (flexible), duloxetine 60mg QD, or placebo...
February 14, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28109109/-role-of-camp-creb-bdnf-signaling-pathway-in-anti-depressive-effect-of-vortioxetine-in-mice
#2
Hui Yu, Jia-Jia Chen, Bing-Qing Zeng, Qiu-Ping Zhong, Jiang-Ping Xu, Yong-Gang Liu
OBJECTIVE: To investigate the effects of vortioxetine on cAMP/CREB/BDNF signal pathway. METHODS: Forty Kunming mice were randomized into control group and chronic unpredictable mild stress (CUMS) group. After establishment of depressive models verified by sucrose preference test, the mice in CUMS group were divided into model group, fluoxetine group and vortioxetine group. The antidepressive effect of vortioxetine was analyzed by tail suspension test, forced swim test and open field test...
January 20, 2017: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/28108062/chronic-vortioxetine-treatment-in-rodents-modulates-gene-expression-of-neurodevelopmental-and-plasticity-markers
#3
Jessica A Waller, Joseph A Tamm, Aicha Abdourahman, Alan L Pehrson, Yan Li, Manuel Cajina, Connie Sánchez
The multimodal antidepressant vortioxetine displays an antidepressant profile distinct from those of conventional selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) and possesses cognitive-enhancing properties in preclinical and clinical studies. Recent studies have begun to investigate molecular mechanisms that may differentiate vortioxetine from other antidepressants. Acute studies in adult rats and chronic studies in a middle-aged mouse model reveal upregulation of several markers that play a central role in synaptic plasticity...
February 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28007563/crystal-structures-x-ray-photoelectron-spectroscopy-thermodynamic-stabilities-and-improved-solubilities-of-two-hydrochloride-salts-of-vortioxetine
#4
Jing Li, Li-Yang Li, Sai-Fei He, Shan Li, Chang-Zhi Dong, Lei Zhang
Two vortioxetine (VOT) salts with hydrochloride (VOT-HCl and VOT-0.5HCl) were prepared and structurally characterized. VOT-HCl features one-dimensional P/M helical chains through N-H···Cl hydrogen bond interactions, while VOT-0.5HCl possesses a one-dimensional zigzag structure in which two VOT molecules share a single proton through N···H(+)···N interactions. VOT-HCl converts into the monohydrate VOT-HCl·H2O after dissolution in water, while VOT-0.5HCl remains stable. The N 1s X-ray photoelectron spectroscopy analysis shows a characteristic binding energy peak at approximately 398...
December 19, 2016: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/27996982/-vortioxetine-in-the-treatment-of-major-depression
#5
Andrea de Bartolomeis, Andrea Fagiolini, Giuseppe Maina
Notwithstanding the high prevalence, functional burden, negative consequences and risk of chronicity of major depressive disorder, few innovative medications have been developed in recent years for the treatment of this heterogeneous disease. Vortioxetine is a multi-modal antidepressant that functions both as serotonin transporter (SERT) inhibitor and as 5-HT3, 5-HT7 and 5-HT1D receptors antagonist, 5-HT1A receptor agonist and 5-HT1B receptor partial agonist. A recent meta-analysis of 11 randomized, double-blind, placebo controlled, acute (6-8 weeks) treatment studies has demonstrated the efficacy of vortioxetine 5-20 mg/day in the treatment of depression, with an increasing effect associated with increasing dose...
November 2016: Rivista di Psichiatria
https://www.readbyqxmd.com/read/27972892/cost-utility-analysis-evaluating-vortioxetine-versus-venlafaxine-xr-and-agomelatine-in-the-treatment-of-major-depressive-disorder-in-taiwan
#6
M Brignone, K Atsou, C Reynaud-Mougin, W Chen, D Milea
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971393/cost-effectiveness-evaluation-of-vortioxetine-in-major-depressive-episode-in-the-uk-setting
#7
L Evitt, N Danchenko, K Atsou, M Brignone, F Diamand, R Campbell
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27941264/a-sensitive-precolumn-derivatization-method-for-determination-of-piperazine-in-vortioxetine-hydrobromide-using-a-c8-column-and-high-performance-liquid-chromatography-mass-spectrometry
#8
Shubo Dong, Zhengyu Yan, Hanyue Yang
A rapid and sensitive high-performance liquid chromatography-mass spectrometry method was established to determine the trace residues of piperazine in vortioxetine hydrobromide. The presence of piperazine was determined by precolumn derivatization with dansyl chloride. Chromatographic separation was performed on a Waters SunFire C8 column (150 × 4.6 mm, 3.5 μm) in gradient elution mode, using formic acid and acetonitrile as mobile phase. Detection was performed in a single quadrupole mass spectrometer in single ion monitoring mode using positive ionization...
2016: Analytical Sciences: the International Journal of the Japan Society for Analytical Chemistry
https://www.readbyqxmd.com/read/27927740/chronic-vortioxetine-treatment-reduces-exaggerated-expression-of-conditioned-fear-memory-and-restores-active-coping-behavior-in-chronically-stressed-rats
#9
Lauren Hatherall, Connie Sánchez, David A Morilak
BACKGROUND: Stress is a risk factor for depression and anxiety disorders, disrupting neuronal processes leading to exaggerated fear and compromised coping behaviors. Current antidepressants are only partially effective. Vortioxetine, a novel multimodal antidepressant, is a serotonin transporter inhibitor; 5-HT3, 5-HT7, and 5-HT1D receptor antagonist; 5-HT1B partial agonist; and 5-HT1A agonist. We have shown that chronic dietary vortioxetine administration reversed stress-induced deficits in cognitive flexibility...
December 29, 2016: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27869048/efficacy-safety-and-tolerability-of-vortioxetine-for-the-treatment-of-major-depressive-disorder-in-patients-aged-55-years-or-older
#10
George G Nomikos, Dapo Tomori, Wei Zhong, John Affinito, William Palo
OBJECTIVE: These post hoc analyses evaluate the efficacy, safety, and tolerability of vortioxetine versus placebo in patients aged ≥55 years with major depressive disorder (MDD). METHODS: Study-level efficacy data from 12 short-term, fixed-dose, randomized, placebo-controlled trials of vortioxetine 5-20 mg/day were assessed using a random-effects meta-analysis. Adverse events (AEs), vital signs, ECG values, liver enzymes, and body weight were pooled from the same studies...
November 21, 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27807822/vortioxetine-a-review-in-cognitive-dysfunction-in-depression
#11
James E Frampton
Vortioxetine (Brintellix(®); Trintellix(®)), a generally efficacious and well tolerated antidepressant agent, is approved in the EU and USA for the treatment of major depressive disorder (MDD) in adults. The drug has a distinctive pharmacological profile (combining inhibition of the serotonin transporter with modulation of multiple serotonin receptors) and has been shown to enhance cognitive performance in various animal models and clinical trials. Across three large, placebo-controlled studies in adults with recurrent MDD, short-term treatment with vortioxetine almost always resulted in statistically significant and clinically meaningful improvements in performance on two objective measures (the Digit Symbol Substitution Test and Rey Auditory Verbal Learning Test) that together cover a broad range of cognitive domains, including executive function, attention, processing speed, learning and memory...
November 2016: Drugs
https://www.readbyqxmd.com/read/27781949/current-and-future-perspectives-on-the-major-depressive-disorder-focus-on-the-new-multimodal-antidepressant-vortioxetine
#12
Laura Orsolini, Carmine Tomasetti, Alessandro Valchera, Felice Iasevoli, Elisabetta Filomena Buonaguro, Michele Fornaro, Annastasia L C Fiengo, Giovanni Martinotti, Federica Vellante, Ilaria Matarazzo, Roberta Vecchiotti, Giampaolo Perna, Marco Di Nicola, Alessandro Carano, Andrea de Bartolomeis, Massimo Di Giannantonio, Domenico De Berardis
BACKGROUND: Vortioxetine (VRX) is a multimodal antidepressant that acts as serotonin (5¬HT) transporter inhibitor as well as 5¬HT3A and 5¬HT7 receptors antagonist, 5¬HT1A and 5¬HT1B receptors partial agonist. It was recently approved in the US and the EU for the treatment of adult patients with Major Depressive Disorder (MDD). OBJECTIVE: The present article aims at systematically reviewing findings of the published and unpublished research on the pharmacological properties, efficacy, safety and tolerability of oral VRX in the treatment of major depressive disorder (MDD)...
October 25, 2016: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/27780334/efficacy-of-vortioxetine-on-cognitive-functioning-in-working-patients-with-major-depressive-disorder
#13
Roger S McIntyre, Ioana Florea, Brigitte Tonnoir, Henrik Loft, Raymond W Lam, Michael Cronquist Christensen
OBJECTIVE: This post hoc analysis investigates the effect of vortioxetine on cognitive functioning and depressive symptoms in working adults with major depressive disorder (MDD). METHODS: Population data from FOCUS, a double-blind, randomized, placebo-controlled study investigating the efficacy of vortioxetine versus placebo on cognitive functioning and depression in patients with MDD, were used to analyze mean change from baseline scores for the Digit Symbol Substitution Test (DSST), Trail Making Test A/B (TMT-A/B), Stroop, and Perceived Deficits Questionnaire (PDQ)...
January 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/27756833/the-frontal-cortex-as-a-network-hub-controlling-mood-and-cognition-probing-its-neurochemical-substrates-for-improved-therapy-of-psychiatric-and-neurological-disorders
#14
Mark J Millan, Jean-Michel Rivet, Alain Gobert
The highly-interconnected and neurochemically-rich frontal cortex plays a crucial role in the regulation of mood and cognition, domains disrupted in depression and other central nervous system disorders, and it is an important site of action for their therapeutic control. For improving our understanding of the function and dysfunction of the frontal cortex, and for identifying improved treatments, quantification of extracellular pools of neuromodulators by microdialysis in freely-moving rodents has proven indispensable...
November 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/27745932/systematic-review-of-randomized-controlled-trials-of-candidate-treatments-for-cognitive-impairment-in-depression-and-methodological-challenges-in-the-field
#15
REVIEW
K W Miskowiak, C V Ott, J Z Petersen, L V Kessing
Cognitive impairment is a core feature of Major Depressive Disorder (MDD) but treatments targeting cognition are lacking. Numerous pre-clinical and clinical studies have investigated potential cognition treatments, but overall the evidence is conflicting. We conducted a systematic search following the PRISMA guidelines on PubMed and PsychInfo to evaluate the extant evidence and methodological challenges in randomized controlled trials (RCTs) of biological, psychological and behavioural candidate treatments targeting cognition in MDD...
December 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27739610/mechanism-and-scope-of-base-controlled-catalyst-free-n-arylation-of-amines-with-unactivated-fluorobenzenes
#16
Christian Borch Jacobsen, Morten Meldal, Frederik Diness
A general method for transition metal-free N-arylation of amines has been developed. Mechanistic studies have revealed that the ability of the base to facilitate the desired amination without promoting unwanted side reactions is the guiding factor. By employing lithium bis(trimethylsilyl)amide as a base the resultant deprotonated amines readily react with a range of unactivated fluorobenzene derivatives. This new arylation method is utilized for the simple two-step synthesis of the antidepressant Vortioxetine...
October 14, 2016: Chemistry: a European Journal
https://www.readbyqxmd.com/read/27738380/treatment-resistant-depression-with-loss-of-antidepressant-response-rapid-acting-antidepressant-action-of-dextromethorphan-a-possible-treatment-bridging-molecule
#17
Edward C Lauterbach
Dextromethorphan (DM) may have ketamine-like rapid-acting, treatment-resistant, and conventional antidepressant effects.(1,2) This reports our initial experience with DM in unipolar Major Depressive Disorder (MDD). A patient with treatment-resistant MDD (failing adequate trials of citalopram and vortioxetine) with loss of antidepressant response (to fluoxetine and bupropion) twice experienced a rapid-acting antidepressant effect within 48 hours of DM administration and lasting 7 days, sustained up to 20 days with daily administration, then gradually developing labile loss of antidepressant response over the ensuing 7 days...
August 15, 2016: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/27725683/a-randomized-placebo-controlled-active-reference-double-blind-flexible-dose-study-of-the-efficacy-of-vortioxetine-on-cognitive-function-in-major-depressive-disorder
#18
Atul R Mahableshwarkar, John Zajecka, William Jacobson, Yinzhong Chen, Richard Se Keefe
No abstract text is available yet for this article.
November 2016: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27698313/structures-and-physicochemical-properties-of-vortioxetine-salts
#19
Xinbo Zhou, Xiurong Hu, Suxiang Wu, Jiali Ye, Mengying Sun, Jianming Gu, Jianrong Zhu, Zhongliang Zhang
In the present work, novel salts of the multimodal antidepressant drug vortioxetine (VT) were crystallized with pharmaceutically acceptable acids, aiming to improve the solubility of VT. The acids for VT were selected based on ΔpKa being greater than 2 or 3. Salts of hydrobromic acid (HBr), hydrochloric acid (HCl), p-hydroxybenzoic acid (PHBA), saccharin (SAC) and L-aspartic acid (ASP) were reported. All salts were characterized by single-crystal X-ray diffraction, FT-IR, powder X-ray diffraction (PXRD) and differential scanning calorimetry (DSC)...
October 1, 2016: Acta Crystallographica Section B, Structural Science, Crystal Engineering and Materials
https://www.readbyqxmd.com/read/27680105/cost-utility-analysis-of-vortioxetine-versus-agomelatine-bupropion-sr-sertraline-and-venlafaxine-xr-after-treatment-switch-in-major-depressive-disorder-in-finland
#20
Erkki Soini, Taru Hallinen, Mélanie Brignone, Rosanne Campbell, Françoise Diamand, Sandrine Cure, Maria Aalto-Setälä, Natalya Danchenko, Hannu J Koponen, Katarzyna Kolasa
OBJECTIVES: To assess the cost-utility of vortioxetine versus relevant comparators (agomelatine, bupropion SR, sertraline, and venlafaxine XR) in the Finnish setting in major depressive disorder (MDD) patients with inadequate response to selective serotonin- /serotonin-norepinephrine reuptake inhibitors. METHODS: A one-year analysis was conducted using a decision tree with a Markov state transition component. The health states were remission, relapse and recovery...
September 29, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
keyword
keyword
22035
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"